Clindamycin Spectrum of Activity
Clindamycin is active against methicillin-susceptible Staphylococcus aureus, most streptococci (excluding enterococci), Streptococcus pneumoniae, and a broad range of anaerobic bacteria including Bacteroides, Clostridium, Fusobacterium, Peptostreptococcus, and Prevotella species. 1
Gram-Positive Aerobic Bacteria
According to FDA labeling, clindamycin demonstrates proven clinical efficacy against:
- Staphylococcus aureus (methicillin-susceptible strains only)
- Streptococcus pneumoniae (penicillin-susceptible strains)
- Streptococcus pyogenes (Group A streptococci)
Additional gram-positive organisms with in vitro susceptibility (≥90% susceptible) but without established clinical trial data include:
- Staphylococcus epidermidis (methicillin-susceptible)
- Streptococcus agalactiae (Group B)
- Streptococcus anginosus, mitis, and oralis 1
Critical caveat: Clindamycin is NOT active against enterococci (Streptococcus faecalis and S. faecium), which are intrinsically resistant 2, 3. This is a common pitfall when treating mixed infections—enterococci will persist despite clindamycin therapy.
Anaerobic Bacteria
Clindamycin demonstrates excellent activity against most clinically significant anaerobes, with proven efficacy against:
Anaerobic gram-positive cocci:
- Peptostreptococcus anaerobius
- Finegoldia (Peptostreptococcus) magna
- Micromonas (Peptostreptococcus) micros 1
Clostridia:
- Clostridium perfringens
- Clostridium clostridioforme 1
Bacteroides species:
- Prevotella melaninogenica
- Prevotella bivia
- Prevotella intermedia 1
Fusobacterium species:
- Fusobacterium necrophorum
- Fusobacterium nucleatum 1
Other anaerobes:
- Actinomyces israelii
- Cutibacterium acnes (formerly Propionibacterium acnes)
- Eggerthella lenta 1
Important Resistance Patterns
Emerging resistance concerns: Recent data from 2026 shows concerning resistance rates in certain anaerobes:
- Prevotella species: 50% clindamycin resistance, 53.3% amoxicillin-clavulanate resistance
- Clostridium perfringens: 43.3% clindamycin resistance 4
This represents a significant shift from historical susceptibility patterns where clindamycin was uniformly active against these organisms 5, 6, 7. When treating serious infections involving Prevotella or selecting clindamycin as primary therapy for significant anaerobic infections, consider obtaining susceptibility testing rather than relying on empiric coverage.
Clinical Application Based on Guidelines
The 2024 WHO guidelines and 2014 IDSA guidelines support clindamycin use for:
- Impetigo: Active against S. aureus and streptococci 8
- Purulent skin/soft tissue infections: Covers S. aureus including some community-acquired MRSA strains 8
- Non-purulent cellulitis: Covers streptococci 8
- Necrotizing fasciitis: Combined with penicillin for Streptococcus species or Clostridium species 8
- Animal bites: Provides anaerobic coverage (though metronidazole preferred) 8
- Diabetic foot infections: Covers gram-positive cocci and anaerobes 8
Key Limitations
Clindamycin has NO activity against:
- Methicillin-resistant S. aureus (MRSA) - though some community-acquired strains may be susceptible, hospital-acquired MRSA is typically resistant
- Enterococci (S. faecalis, S. faecium)
- Gram-negative aerobes (Enterobacteriaceae, Pseudomonas)
- Eikenella corrodens (relevant in human bite wounds) 9
Resistance mechanism: Macrolide-resistant staphylococci and streptococci should be screened with D-zone testing, as macrolide resistance can induce clindamycin resistance even when initial testing suggests susceptibility 1.